Insights

Professional
Practice
Industry
Region
Trending Topics
Location
Type

Sort by:

Firm News 44 results

Firm News | 2 min read | 04.23.25

Laura Lydigsen and Jason Stiehl Named to Crain’s Chicago Business 2025 Notable Litigators & Trial Attorneys List

Chicago – April 23, 2024: Laura Lydigsen, co-chair of Crowell & Moring’s Intellectual Property Department, and Jason Stiehl, managing partner of the firm’s Chicago office, have been named to Crain’s Chicago Business’ 2025 list of Notable Litigators & Trial Attorneys. The list features 92 attorneys shaping Chicago's legal landscape from high-stakes litigation to precedent-setting appellate rulings.

Firm News | 3 min read | 04.01.24

Crowell Earns Top Rankings in Legal 500 EMEA 2024

Brussels and Doha – April 1, 2024: The Legal 500 Europe, Middle East & Africa (EMEA) 2024 edition has recognized 16 practice areas and 11 lawyers in Crowell & Moring’s Brussels and Doha offices. The 11 individual lawyers received 18 total rankings across the 16 different practice areas.
...

Firm News | 2 min read | 03.14.24

Chambers Ranks Crowell Lawyers and Practices in 2024 Europe Guide

Chambers and Partners has ranked five Crowell & Moring practice groups and seven individual lawyers in the Chambers Europe 2024 guide.

Client Alerts 75 results

Client Alert | 4 min read | 04.10.25

Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”

In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
...

Client Alert | 4 min read | 04.01.25

Hatch-Waxman PTE for Reissue Patents Should Be Calculated From the Original Patent’s Issue Date

On March 13, 2025, the United States Court of Appeals for the Federal Circuit issued a decision about Patent Term Extensions (PTEs) under the Hatch-Waxman Act for reissue patents. In Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (No. 2023-2254), the Court confirmed that the PTE provision under 35 U.S.C. § 156 refers to the original patent’s issue date, not the reissue patent’s issue date. Thus, the issue date of the original patent should be used when calculating the extension period.
...

Client Alert | 4 min read | 03.27.25

Proposed Bills Limit Pharmaceutical Patents: Panacea for Patients or Poison for Pharmaceutical Producers?

Senators John Cornyn(R-Texas), Chuck Grassley (R-Iowa), Richard Blumenthal (D-Conn.), and Dick Durbin (D.-Ill.) recently sponsored two bills, introduced on March 14th, that would affect patents in the pharmaceutical industry.
...

Press Coverage 8 results

Publications 23 results

Publication | 01.15.25

Product Liability: Class Actions Are Increasingly Using Economic Loss To Bring Claims

A trend in product liability litigation has emerged over the past few years: Plaintiffs’ attorneys are increasingly choosing to bring class actions based on “economic loss” instead of the more traditional personal injury claim.
...

Events 4 results

Event | 02.25.25, 5:00 PM EST - 8:00 PM EST

Charting a Path for Compliance in Life Sciences

Join us for an interactive and educational event tailored for biotech leaders seeking to ensure security compliance while leveraging the power of Amazon Web Services (AWS). This session will dive into the critical elements of designing secure, scalable, and compliant systems for biotech operations, from research and development to clinical trials and beyond.
...

Event | 12.03.24, 8:30 AM EST - 9:30 AM EST

29th Annual Drug & Medical Device Litigation Conference

2024 has been a pivotal year for drug and medical device litigation, marked by significant case law developments that have reshape the landscape.

Event | 10.24.24, 5:30 PM EDT - 7:30 PM EDT

Do We Need a New Approach for Investing and Raising Funds in This Election Cycle?: A Fireside Chat and Networking Event for Emerging Companies and Investors

Join us for a networking event co-hosted by NYBIO and Crowell & Moring on October 24 between 5:30 and 7:30 pm. We will kick off the evening with a fireside chat moderated by Linda Malek, partner in the Healthcare and Privacy/Cybersecurity practices at Crowell in discussion with Andrew Lam, Managing Director and Head of Biotech Private Equity, Ally Bridge Group and Prem Premsrirut, Founder and CEO, Mirimus Inc. and Executive Director of Micoy Therapeutics.

Speaking Engagements 28 results

Blog Posts 3 results

Blog Post | 10.29.21

FDA Publishes Principles for AI and ML in Medical Devices

Crowell & Moring's Health Law Blog

Blog Post | 07.27.16

Beauty with a Side of Mercury?

Crowell & Moring's Retail & Consumer Products Law Observer